Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration

被引:127
作者
Bartels, Anna L. [1 ]
Kortekaas, Rudie [2 ]
Bart, Joost [3 ]
Willemsen, Antoon T. M. [4 ]
de Klerk, Onno L. [5 ]
de Vries, Jeroen J. [1 ]
van Oostrom, Joost C. H. [1 ]
Leenders, Klaus L. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Anat, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9700 RB Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 RB Groningen, Netherlands
关键词
Aging; P-glycoprotein; PET; C-11]-verapamil; Blood-brain barrier; Neurodegeneration; Alzheimer; Parkinson; White matter; POSITRON-EMISSION-TOMOGRAPHY; MULTIDRUG-RESISTANCE GENE; PARKINSONS-DISEASE; IN-VIVO; AMYLOID-BETA; ALZHEIMERS-DISEASE; ABC TRANSPORTERS; POTENTIAL ROLE; MOUSE-BRAIN; MDR1; GENE;
D O I
10.1016/j.neurobiolaging.2008.02.002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Cerebrovascular P-glycoprotein (P-gp) acts at the blood-brain barrier (BBB) as an active cell membrane efflux pump for several endogenous and exogenous compounds. Age-associated decline in P-gp function could facilitate the accumulation of toxic substances in the brain, thus increasing the risk of neurodegenerative pathology with aging. We hypothesised a regionally reduced BBB P-gp function in older healthy subjects. We studied cerebrovascular P-gp function using [C-11]-verapamil positron emission tomography (PET) in seventeen healthy volunteers with age 18-86. Logan analysis was used to calculate the distribution volume (DV) of [C-11]-verapamil in the brain. Statistical Parametric Mapping was used to study specific regional differences between the older compared with the younger adults. Older subjects showed significantly decreased P-gp function in internal capsule and corona radiata white matter and in orbitofrontal regions. Decreased BBB P-gp function in those regions could thus explain part of the vulnerability of the aging brain to white matter degeneration. Moreover, decreased BBB P-gp function with aging could be a mechanism by which age acts as the main risk factor for the development of neurodegenerative disease. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1818 / 1824
页数:7
相关论文
共 50 条
[1]   Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET [J].
Bart, J ;
Willemsen, ATM ;
Groen, HJM ;
van der Graaf, WTA ;
Wegman, TD ;
Vaalburg, W ;
de Vries, EGE ;
Hendrikse, NH .
NEUROIMAGE, 2003, 20 (03) :1775-1782
[2]   Long-term accumulation of amyloid-β, β-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma [J].
Chen, XH ;
Siman, R ;
Iwata, A ;
Meaney, DF ;
Trojanowsko, JQ ;
Smith, DH .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (02) :357-371
[3]   P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model [J].
Cirrito, JR ;
Deane, R ;
Fagan, AM ;
Spinner, ML ;
Parsadanian, M ;
Finn, MB ;
Jiang, H ;
Prior, JL ;
Sagare, A ;
Bales, KR ;
Paul, SM ;
Zlokovic, BV ;
Piwnica-Worms, D ;
Holtzman, DM .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3285-3290
[4]   Potential role of ABC transporters as a detoxification system at the blood-CSF barrier [J].
de Lange, ECM .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (12) :1793-1809
[5]   Isolation of endothelial cells from brain, lung, and kidney:: Expression of the multidrug resistance P-glycoprotein isoforms [J].
Demeule, M ;
Labelle, M ;
Régina, A ;
Berthelet, F ;
Béliveau, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (03) :827-834
[6]   The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? [J].
Di Monte, DA .
LANCET NEUROLOGY, 2003, 2 (09) :531-538
[7]   Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease [J].
Drozdzik, M ;
Bialecka, M ;
Mysliwiec, K ;
Honczarenko, K ;
Stankiewicz, J ;
Sych, Z .
PHARMACOGENETICS, 2003, 13 (05) :259-263
[8]   In vitro characterization of Pittsburgh compound-B binding to Lewy bodies [J].
Fodero-Tavoletti, Michelle T. ;
Smith, David P. ;
McLean, Catriona A. ;
Adlard, Paul A. ;
Barnham, Kevin J. ;
Foster, Lisa E. ;
Leone, Laura ;
Perez, Keyla ;
Cortes, Mikhalina ;
Culvenor, Janetta G. ;
Li, Qiao-Xin ;
Laughton, Katrina M. ;
Rowe, Christopher C. ;
Masters, Colin L. ;
Cappai, Roberto ;
Villemagne, Victor L. .
JOURNAL OF NEUROSCIENCE, 2007, 27 (39) :10365-10371
[9]   COMPARING FUNCTIONAL (PET) IMAGES - THE ASSESSMENT OF SIGNIFICANT CHANGE [J].
FRISTON, KJ ;
FRITH, CD ;
LIDDLE, PF ;
FRACKOWIAK, RSJ .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1991, 11 (04) :690-699
[10]   Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease [J].
Furuno, T ;
Landi, MT ;
Ceroni, M ;
Caporaso, N ;
Bernucci, I ;
Nappi, G ;
Martignoni, E ;
Schaeffeler, E ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2002, 12 (07) :529-534